Retatrutide 20mg Vial

Retatrutide (LY3437943) — a next-generation triple-agonist research peptide, supplied as a 20mg lyophilised vial. Ships with a free 2ml vial of bacteriostatic water.

About

Retatrutide is a novel triple-agonist peptide developed by Eli Lilly, acting simultaneously on the GIP, GLP-1 and glucagon receptors. It is the successor to the tirzepatide (dual GIP/GLP-1) programme and has attracted strong interest in obesity, metabolic and body-composition research for its multi-receptor mechanism.

Supplied as a lyophilised (freeze-dried) powder in a sealed sterile vial for laboratory reconstitution.

At a glance

• Compound: Retatrutide (LY3437943)
• Class: GIP / GLP-1 / glucagon triple-receptor agonist peptide
• Amount: 20mg per vial
• Form: Lyophilised powder (sterile sealed vial)
• Purity: >99%
• Included: 2ml bacteriostatic water vial (free with every purchase)
• Storage: Refrigerate lyophilised vial. Once reconstituted, store at 2–8°C and use within 28 days.

Reconstitution

Reconstitute with the supplied bacteriostatic water prior to laboratory use. Final concentration depends on the volume of BAC water used — calculate based on your research protocol.

Strictly for research use only. Not for human consumption. Not for use in food, cosmetic, or therapeutic products. Must be 18+ to purchase. Compliance with applicable local laws is the buyer's responsibility.